Exhibit B

PTO/SB/08A (04-07) Approved for use through 09/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE Application Filing Date

STATEMENT BY APPLICANT
(Use as many sheets as necessary)

 Complete if Known

 Application Number
 10/650,365

 Filing Date
 August 28, 2003

 First Named Inventor
 Guangwen WEI

 Art Unit
 1646

 Examiner Name
 Bruce D. Hissong

 Attorney Docket Number
 792-A-PCT-US

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (Yinson)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passagas or Relevan Figures Appear		
	1	us- 6,114,145	09-05-2000	OLSEN et al.			
		US-					
	\vdash	US-					
		US-					
		US-					
		US-					
	_	US-					
		US-					
		US-	-				
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	†	US-					
	 	US-					
		US-			+		

2	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known) WO 2005/034853 A2			
	VVO 2003/034033 AZ	04-21-2005	HUIYANGTECH (INC.) USA	
3	AU 2003248419	11-06-2003	WEI et al.	
4	CN 1375502A	11-23-2002	YAO et al.	
5	CN 1478545A	03-03-2004	GAO et al.	

Examiner Signature	Date Considered	

"EXAMINET: Initial if reference considered, whether or not otation is in conformance with MPEP 609. Their line through citation in find in conformance and not considered, include copy of this form with next communication to applicant. "Applicants' unique sclade designation number (collocation and USFTO Patient Documents at www.upsign.org/ or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patient foocoments, the indication of the year of the regind of the Competer must precede the senial number of the partent countering the depropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark there if English language Translation is attached.

This odlection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO by process) an application. Confidentially is powered by 35 US, 6.12 and 37 CPR 1.91 4.1 This collection is estimated to Exhaus to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of this your require to complete this form ander suggestions for reducing this burden, about the sent to the Chief Information Confidence, U.S. Patient and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patinats, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07) Approved for use through 09/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Unc	er the Paperwork Red	uction A	t of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number.	
Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/650,365	
			CLOSURE	Filing Date	August 28, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Guangwen WEI	
	(Use as many she	ets as n	ecessary)	Art Unit	1646	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Examiner Name	Bruce D. Hissong	
Sheet	2	of	4	Attorney Docket Number	792-A-PCT-US	

		NON PATENT LITERATURE DOCUMENTS	
Initials* No.1 the item (book, magazine, journal, serial, symposium, ca		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Written Opinion of the International Searching Authority for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2004.	
	4	International Search Report for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2005.	
	8	Ivan AMATO, January 22, 2007, "Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.	
	9	AUSUBEL et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," from Short Protocols in Molecular Biology, 4th ed., p. 10-1 to 10-8.	
	10	CINATL et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.	
	11	DAY et al., 1992, "Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-beta," Journal of Interferon Res., 12: 139-143.	
	12	DUAN et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.	
	13	HIGGINS et al., 1983, "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy, 24(5):713-715.	
	14	HOLLAND, C.C. and T.L. WRIGHT, 1994, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 3(1).	
	15	NACKLEY, A.G. et al., December 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.	

Examiner		Date	
Signature		Considered	
*EXAMINER: In	nitial if reference considered, whether or not citation is in conformance with MPED 80	O Draw line through o	itation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to approach.

1 Applicant's unique clation designation number (options). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 3° CFR 1.88. The information is required to obtain or retain a benefit by the public which is to fire (and by the USPTO to process) an application. Confidentially is governed by 5° US. C. 122 and 5° CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. This will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Un	der the Paperwork Rec	luction A	at of 1995, no persons as	e required to respond to a collection	of information unless it contains a valid OMB control number.		
Substitu	te for form 1449/PTO			Complete if Known			
				Application Number	10/650,365		
			CLOSURE	Filing Date	August 28, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Guangwen WEI		
	(Use as many she	ets as n	ecessaryl	Art Unit 1646			
	(000 00 11111)			Examiner Name	Bruce D. Hissong		
Sheet	3	of	4	Attorney Docket Number	792-A-PCT-US		

	-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	NASOFF et al., 1999, "High-level expression of human genes in E. coli," Expression, 6(2): 10-11.	
	17	PYRC, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders – Drug Targets, 7:59-66.	
	18	ZHAO, Z. et al., 2003, "Description and clinical treatment of an early outbreak of Severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol., 52:715-720.	
	19	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated April 3, 2007.	
	20	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated June 14, 2007.	
	21	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated December 15, 2006.	
	22	Advisory Action Before the Filing of an Appeal Brief for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated May 22, 2007.	
	23	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 9, 2007.	
	24	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated February 9, 2007.	
	25	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 22, 2006.	

Signature		Considered	
	itial if reference considered, whether or not citation is in conformance with MPEP 60	Draw line through c	itation if not in conformance and not
considered. Inc	lude copy of this form with next communication to applicant.		

Evaminer

considered. Include copy of the form with neutron consultation to papie and 1.4 popiciants unique classion designation make regionation. 2.4 papicants is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain abone to benefit by the public which is to file (and by the USPTO to process) an application. Confiderability is governed by 53 U.S. C. 122 and 75 CFR 1.14. This result is collected by a submitting the completed application from the USPTO. This will very depend upon the individual case. Any comments on the amount of time by or require to complete in form and output of the complete depictation and the complete depictation of the USPTO. This will very depth upon the USPTO of the Information Conficer, U.S. Patent and Tradeout of the USPTO o

PTQ/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Un	der the Paperwork Rec	duction A	ct of 1995, no persons as	e required to respond to a collection	of information unless it contains a valid OMB control number.		
Substitu	te for form 1449/PTO			Complete if Known			
				Application Number	10/650,365		
			CLOSURE	Filing Date	August 28, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Guangwen WEI		
	(Use as many she	eets as n	ecessanh	Art Unit	1646		
	(Ode as many sin	, cua da 11	ecessary	Examiner Name	Bruce D. Hissong		
Sheet	4	of	4	Attorney Docket Number	792-A-PCT-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	26	U.S Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 1, 2007.	
	27	U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated November 27, 2006.	
	28	U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 8, 2006.	
	29	U.S Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated September 19, 2007.	

ı	Examiner		Date	
	Signature		Considered	
	*EXAMINER: In	itial if reference considered, whether or not citation is in conformance with MPEP 609	Draw line through o	itation if not in conformance and not
	considered. Inc	fude copy of this form with next communication to applicant.		

considered. Include copy of this form with eact communication to applicant.

1 Applicant's unique catation designation number (options) 2. Applicant is unique testion of designation is attached.

This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to collection of information is required by 37 CFR 1.38. This of Training is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is a powered by 35 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 2 puts to complete, including pathening, preparing, and submitting the completed application from to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time by one require to complete his form and/or suggestions for reducing this burdon, aloued be seet to the Other Information Officer, U.S. Patent and Tradeoff Cff. 20. Patent and Trad